Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1980 Jan;55(1):49–53. doi: 10.1136/adc.55.1.49

Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.

Y Seino, T Shimotsuji, T Ishii, M Ishida, C Ikehara, K Yamaoka, H Yabuuchi, S Dokoh
PMCID: PMC1626736  PMID: 6246841

Abstract

Plasma levels of 1,25 dihydroxy-vitamin D (1,25-(OH)2-D) were low in 3 children with hypophosphataemic vitamin D-resistant rickets (HVDRR) during childhood, but increased after very large doses (0.5 to 2 micrograms/kg per day) of 1 alpha-hydroxy-vitamin D (1 alpha-OH-D3). This treatment has two advantages. Firstly, hypercalcaemia is easily controlled by reducing the dose of 1 alpha-OH-D3 because of its short half-life. Secondly, the administration of 1 alpha-OH-D3 to patients with HVDRR can enhance the tubular reabsorption of phosphate, and this seems desirable in treating HVDRR.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balsan S., Garabedian M., Sorgniard R., Holick M. F., Deluca H. F. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance. Pediatr Res. 1975 Jul;9(7):586–593. doi: 10.1203/00006450-197507000-00007. [DOI] [PubMed] [Google Scholar]
  2. Corvilain J., Abramow M. Growth and renal control of plasma phosphate. J Clin Endocrinol Metab. 1972 Mar;34(3):452–459. doi: 10.1210/jcem-34-3-452. [DOI] [PubMed] [Google Scholar]
  3. Dokoh S., Morita R., Fukunaga M., Yamamoto I., Torizuka K. Competitive protein binding assay for 1,25-dihydroxy-vitamin D in human plasma. Endocrinol Jpn. 1978 Oct;25(5):431–436. doi: 10.1507/endocrj1954.25.431. [DOI] [PubMed] [Google Scholar]
  4. Eisman J. A., Hamstra A. J., Kream B. E., DeLuca H. F. A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma. Arch Biochem Biophys. 1976 Sep;176(1):235–243. doi: 10.1016/0003-9861(76)90161-2. [DOI] [PubMed] [Google Scholar]
  5. Fukushima M., Suzuki Y., Toira Y., Matsunaga I., Ochi K., Nagano H. Metabolism of 1alpha-hydroxyvitamin D3 to 1alpha, 25-dihydroxyvitamin D3 in perfused rat liver. Biochem Biophys Res Commun. 1975 Sep 16;66(2):632–638. doi: 10.1016/0006-291x(75)90556-2. [DOI] [PubMed] [Google Scholar]
  6. Kanis J. A., Russell R. G. Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J. 1977 Jan 8;1(6053):78–81. doi: 10.1136/bmj.1.6053.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Robertson I., Boddy K., Hooper M. J., Stevenson R. D., McGhie T., Alexander W. D., Wilson G. M. Total thyroidal content of iodine in thyrotoxic patients measured by in vivo neutron activation analysis. Clin Endocrinol (Oxf) 1976 Mar;5(2):151–157. doi: 10.1111/j.1365-2265.1976.tb02826.x. [DOI] [PubMed] [Google Scholar]
  8. Seino Y., Shimotsuji T., Kai H., Ikehara C., Yabuuchi H. The plasma levels of 25-hydroxyvitamin D in patients with various liver diseases and the response of 25-hydroxyvitamin D to vitamin D treatment. Acta Paediatr Scand. 1978 Jan;67(1):39–42. doi: 10.1111/j.1651-2227.1978.tb16274.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES